KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity. In Vitro KYN-101 (0.5, 1 µM; 24 h) decreases the CYP1A1 mRNA expression in IDO high samples. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo KYN-101 (10 mg/kg; p.o.; daily for 12 days) shows anti-cancer activity in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice) Dosage: 10 mg/kg Administration: P.o.; daily for 12 days Result: Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
KYN-101
CAS number：2247950-73-6 molecular formula：C22H19FN6
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2247950-73-6 | molecular formula | C22H19FN6 |
| molecular weight | 386.42 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
